Equities Analysts Set Expectations for SABS Q3 Earnings

SAB Biotherapeutics, Inc. (NASDAQ:SABS) – Analysts at Brookline Capital Markets raised their Q3 2026 earnings estimates for SAB Biotherapeutics in a report released on Thursday, August 6th. Brookline Capital Markets analyst K. Raja now anticipates that the company will earn ($0.24) per share for the quarter, up from their prior forecast of ($0.25). The consensus estimate for SAB Biotherapeutics’ current full-year earnings is ($1.21) per share. Brookline Capital Markets also issued estimates for SAB Biotherapeutics’ Q4 2026 earnings at ($0.24) EPS, FY2027 earnings at ($0.95) EPS, FY2028 earnings at ($0.95) EPS and FY2029 earnings at $0.48 EPS.

Several other analysts have also commented on the company. Chardan Capital raised their target price on SAB Biotherapeutics from $14.00 to $16.00 and gave the stock a “buy” rating in a report on Wednesday, June 17th. Zacks Research upgraded SAB Biotherapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, May 11th. Leerink Partners upped their price objective on SAB Biotherapeutics from $7.00 to $12.00 and gave the stock an “outperform” rating in a research report on Monday, June 15th. Jefferies Financial Group started coverage on shares of SAB Biotherapeutics in a research note on Wednesday, May 20th. They set a “buy” rating and a $11.00 price objective on the stock. Finally, Citigroup assumed coverage on shares of SAB Biotherapeutics in a report on Friday, May 22nd. They set a “buy” rating and a $11.00 target price for the company. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $12.00.

SAB Biotherapeutics Stock Performance

Shares of SABS stock opened at $3.78 on Monday. SAB Biotherapeutics has a 52-week low of $1.85 and a 52-week high of $5.15. The company has a quick ratio of 9.22, a current ratio of 9.22 and a debt-to-equity ratio of 0.01. The stock has a market cap of $343.94 million, a PE ratio of -2.91 and a beta of 0.53. The business has a 50-day simple moving average of $3.69 and a 200-day simple moving average of $3.83.

SAB Biotherapeutics (NASDAQ:SABS) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.28) earnings per share for the quarter, hitting the consensus estimate of ($0.28).

Institutional Investors Weigh In On SAB Biotherapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in SABS. Seven Fleet Capital Management LP acquired a new stake in SAB Biotherapeutics in the 1st quarter worth about $1,915,000. Simplify Asset Management Inc. purchased a new stake in SAB Biotherapeutics during the 4th quarter worth approximately $779,000. Propel Bio Management LLC acquired a new position in shares of SAB Biotherapeutics during the fourth quarter valued at approximately $2,442,000. Perceptive Advisors LLC raised its holdings in shares of SAB Biotherapeutics by 700.8% during the first quarter. Perceptive Advisors LLC now owns 6,431,743 shares of the company’s stock valued at $24,634,000 after acquiring an additional 5,628,533 shares during the last quarter. Finally, DV Trading LLC purchased a new position in shares of SAB Biotherapeutics in the first quarter valued at approximately $1,532,000. Hedge funds and other institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.